TCM
PCVX icon

Tekla Capital Management’s Vaxcyte PCVX Stock Holding History

Tekla Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$9.7M Buy
194,232
+189,232
+3,785% +$8.97M 0.38% 58
2023
Q1 		$187K Hold
5,000
– – 0.01% 166
2022
Q4 		$240K Buy
+5,000
New +$196K 0.01% 159

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tekla Capital Management's PCVX Position: Q2 2023 in Review

Tekla Capital Management increased its Vaxcyte (PCVX) stake by 3,785% in Q2 2023, buying an estimated $8.97M and bringing the position to 194,232 shares worth $9.7M. The position accounts for 0.38% of the portfolio, ranked #58.

Tekla Capital Management first reported a position in PCVX in Q4 2022 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • Tekla Capital Management held 194,232 shares of Vaxcyte worth $9.7M as of Q2 2023.
  • Tekla Capital Management bought 189,232 Vaxcyte shares in Q2 2023, an estimated $8.97M.
  • Vaxcyte made up 0.38% of Tekla Capital Management's portfolio in Q2 2023, its #58 holding.
  • Tekla Capital Management first reported a position in Vaxcyte in Q4 2022 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.